-
Je něco špatně v tomto záznamu ?
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
JC. Bennett, MK. Hetrich, M. Garcia Quesada, JN. Sinkevitch, M. Deloria Knoll, DR. Feikin, SL. Zeger, EW. Kagucia, AL. Cohen, K. Ampofo, MC. Brandileone, D. Bruden, R. Camilli, J. Castilla, G. Chan, H. Cook, JE. Cornick, R. Dagan, T. Dalby, K....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
001
World Health Organization - International
INV-010429 / OPP1189065
Bill and Melinda Gates Foundation
NLK
Directory of Open Access Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2013-01-01
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- Publikační typ
- časopisecké články MeSH
Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for <5 years of age, 0.08 (0.06-0.09) for 5-17 years, 0.06 (0.05-0.08) for 18-49 years, 0.06 (0.05-0.07) for 50-64 years, and 0.05 (0.04-0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.
Bacteria Parasites and Fungi Statens Serum Institut DK 2300 Copenhagen Denmark
Centers for Disease Control and Prevention Nairobi Kenya
Centre for Disease Control Department of Health and Community Services Darwin NT 8000 Australia
Centre for Disease Prevention and Control of Latvia 1005 Riga Latvia
Child Health Research Foundation Dhaka 1207 Bangladesh
CIBER Epidemiología y Salud Pública 28029 Madrid Spain
Communicable Diseases Centre National Institute of Public Health 1000 Ljubljana Slovenia
Department of Health Security Finnish Institute for Health and Welfare 00271 Helsinki Finland
Department of Infection Control and Vaccine Norwegian Institute of Public Health 0456 Oslo Norway
Department of Infectious Diseases Italian National Institute of Health 00161 Rome Italy
Department of Microbiology Immunology and Transplantation KU Leuven BE 3000 Leuven Belgium
Department of Microbiology Public Health Agency of Sweden 171 82 Solna Sweden
Department of Pediatrics University of Calgary and Alberta Health Services Calgary AB T3B 6A8 Canada
Department of Pediatrics Yale New Haven Children's Hospital New Haven CT 06504 USA
Department of Social and Preventive Medicine Laval University Québec QC G1V 0A6 Canada
Doctoral Studies Department Riga Stradinš University 1007 Riga Latvia
Epidemiology Department Dirección General de Salud Pública 28009 Madrid Spain
Faculty of Health Sciences Ben Gurion University of the Negev 8410501 Beer Sheva Israel
Health Sciences Unit Faculty of Social Sciences University of Tampere 33100 Tampere Finland
HSE Health Protection Surveillance Centre Mountjoy Dublin D01 A4A3 Ireland
Immunisation and Countermeasures Division Public Health England London NW9 5EQ UK
Independent Consultant 1296 Coppet Switzerland
Instituto de Salud Pública de Chile 7780050 Santiago Santiago Metropolitan Chile
Instituto de Salud Pública de Navarra IdiSNA 31003 Pamplona Navarra Spain
Johns Hopkins Bloomberg School of Public Health Baltimore MD 21205 USA
Malawi Liverpool Wellcome Trust Clinical Research Programme P O Box 30096 Chichiri Blantyre 3 Malawi
Medicine Department Universitat Internacional de Catalunya 08017 Barcelona Spain
Ministry of Health and Medical Services Suva Fiji
National Institute for Public Health and the Environment 3721 MA Bilthoven The Netherlands
National Institute of Public Health 100 42 Praha Czech Republic
National Public Health Organisation 15123 Athens Greece
National Reference Centre for Bacterial Meningitis National Medicines Institute 00 725 Warsaw Poland
New Vaccines Group Murdoch Children's Research Institute Parkville Melbourne 3052 Victoria Australia
Public Health Scotland Glasgow G2 6QE UK
Singapore Ministry of Health Communicable Diseases Division Singapore 308442 Singapore
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018082
- 003
- CZ-PrNML
- 005
- 20210729104129.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/microorganisms9040696 $2 doi
- 035 __
- $a (PubMed)33801760
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bennett, Julia C $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 245 10
- $a Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project / $c JC. Bennett, MK. Hetrich, M. Garcia Quesada, JN. Sinkevitch, M. Deloria Knoll, DR. Feikin, SL. Zeger, EW. Kagucia, AL. Cohen, K. Ampofo, MC. Brandileone, D. Bruden, R. Camilli, J. Castilla, G. Chan, H. Cook, JE. Cornick, R. Dagan, T. Dalby, K. Danis, S. de Miguel, P. De Wals, S. Desmet, T. Georgakopoulou, C. Gilkison, M. Grgic-Vitek, LL. Hammitt, M. Hilty, PL. Ho, S. Jayasinghe, JD. Kellner, J. Kleynhans, MJ. Knol, J. Kozakova, KG. Kristinsson, SN. Ladhani, L. MacDonald, GA. Mackenzie, L. Mad'arová, A. McGeer, J. Mereckiene, E. Morfeldt, T. Mungun, C. Muñoz-Almagro, JP. Nuorti, M. Paragi, T. Pilishvili, R. Puentes, SK. Saha, A. Sahu Khan, L. Savrasova, JA. Scott, A. Skoczyńska, S. Suga, M. van der Linden, JR. Verani, A. von Gottberg, BA. Winje, I. Yildirim, K. Zerouali, K. Hayford, . The Pserenade Team
- 520 9_
- $a Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for <5 years of age, 0.08 (0.06-0.09) for 5-17 years, 0.06 (0.05-0.08) for 18-49 years, 0.06 (0.05-0.07) for 50-64 years, and 0.05 (0.04-0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hetrich, Marissa K $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Garcia Quesada, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Sinkevitch, Jenna N $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Deloria Knoll, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Feikin, Daniel R $u Independent Consultant, 1296 Coppet, Switzerland
- 700 1_
- $a Zeger, Scott L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Kagucia, Eunice W $u KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Cohen, Adam L $u World Health Organization, 1202 Geneva, Switzerland
- 700 1_
- $a Ampofo, Krow $u Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
- 700 1_
- $a Brandileone, Maria-Cristina C $u National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil
- 700 1_
- $a Bruden, Dana $u Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK 99508, USA
- 700 1_
- $a Camilli, Romina $u Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy
- 700 1_
- $a Castilla, Jesús $u CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain $u Instituto de Salud Pública de Navarra-IdiSNA, 31003 Pamplona, Navarra, Spain
- 700 1_
- $a Chan, Guanhao $u Singapore Ministry of Health, Communicable Diseases Division, Singapore 308442, Singapore
- 700 1_
- $a Cook, Heather $u Centre for Disease Control, Department of Health and Community Services, Darwin, NT 8000, Australia
- 700 1_
- $a Cornick, Jennifer E $u Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool CH64 7TE, UK $u Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre 3, Malawi
- 700 1_
- $a Dagan, Ron $u Faculty of Health Sciences, Ben-Gurion University of the Negev, 8410501 Beer-Sheva, Israel
- 700 1_
- $a Dalby, Tine $u Bacteria, Parasites and Fungi, Statens Serum Institut, DK-2300 Copenhagen, Denmark
- 700 1_
- $a Danis, Kostas $u Santé Publique France, the French National Public Health Agency, Saint Maurice CEDEX, 94415 Paris, France
- 700 1_
- $a de Miguel, Sara $u Epidemiology Department, Dirección General de Salud Pública, 28009 Madrid, Spain
- 700 1_
- $a De Wals, Philippe $u Department of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada
- 700 1_
- $a Desmet, Stefanie $u Department of Microbiology, Immunology and Transplantation, KU Leuven, BE-3000 Leuven, Belgium $u National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, 3000 Leuven, Belgium
- 700 1_
- $a Georgakopoulou, Theano $u National Public Health Organisation, 15123 Athens, Greece
- 700 1_
- $a Gilkison, Charlotte $u Epidemiology Team, Institute of Environmental Science and Research, Porirua, 5240 Wellington, New Zealand
- 700 1_
- $a Grgic-Vitek, Marta $u Communicable Diseases Centre, National Institute of Public Health, 1000 Ljubljana, Slovenia
- 700 1_
- $a Hammitt, Laura L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA $u KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Hilty, Markus $u Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland
- 700 1_
- $a Ho, Pak-Leung $u Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China
- 700 1_
- $a Jayasinghe, Sanjay $u National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia
- 700 1_
- $a Kellner, James D $u Department of Pediatrics, University of Calgary, and Alberta Health Services, Calgary, AB T3B 6A8, Canada
- 700 1_
- $a Kleynhans, Jackie $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 2192 Johannesburg, South Africa $u School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, 2000 Johannesburg, South Africa
- 700 1_
- $a Knol, Mirjam J $u National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health (NIPH), 100 42, Praha Czech Republic
- 700 1_
- $a Kristinsson, Karl G $u Department of Clinical Microbiology, Landspitali-The National University Hospital, Hringbraut, 101 Reykjavik, Iceland
- 700 1_
- $a Ladhani, Shamez N $u Immunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK
- 700 1_
- $a MacDonald, Laura $u Public Health Scotland, Glasgow G2 6QE, UK
- 700 1_
- $a Mackenzie, Grant A $u Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London, WC1E 7HT, UK $u Medical Research Council Unit the Gambia atLondon School of Hygiene & Tropical Medicine, P.O. Box 273, Banjul, The Gambia $u New Vaccines Group, Murdoch Children's Research Institute, Parkville, Melbourne, 3052, Victoria, Australia
- 700 1_
- $a Mad'arová, Lucia $u National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, 975 56 Banská Bystrica, Slovakia
- 700 1_
- $a McGeer, Allison $u Toronto Invasive Bacterial Diseases Network, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
- 700 1_
- $a Mereckiene, Jolita $u HSE Health Protection Surveillance Centre, Mountjoy, Dublin D01 A4A3, Ireland
- 700 1_
- $a Morfeldt, Eva $u Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden
- 700 1_
- $a Mungun, Tuya $u National Center of Communicable Diseases (NCCD), Ministry of Health, Bayanzurkh District, Ulaanbaatar 13336, Mongolia
- 700 1_
- $a Muñoz-Almagro, Carmen $u CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain $u Medicine Department, Universitat Internacional de Catalunya, 08017 Barcelona, Spain $u Molecular Microbiology Department, Hospital Sant Joan de Déu Research Institute, 08950 Esplugues de Llobregat, Barcelona, Spain
- 700 1_
- $a Nuorti, J Pekka $u Department of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland $u Health Sciences Unit, Faculty of Social Sciences, University of Tampere, 33100 Tampere, Finland
- 700 1_
- $a Paragi, Metka $u Centre for Medical Microbiology, National Laboratory of Health, Environment and Food, 2000 Maribor, Slovenia
- 700 1_
- $a Pilishvili, Tamara $u National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
- 700 1_
- $a Puentes, Rodrigo $u Instituto de Salud Pública de Chile, 7780050 Santiago, Santiago Metropolitan, Chile
- 700 1_
- $a Saha, Samir K $u Child Health Research Foundation, Dhaka 1207, Bangladesh
- 700 1_
- $a Sahu Khan, Aalisha $u Ministry of Health and Medical Services, Suva, Fiji
- 700 1_
- $a Savrasova, Larisa $u Centre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia $u Doctoral Studies Department, Riga Stradinš University, 1007 Riga, Latvia
- 700 1_
- $a Scott, J Anthony $u KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Skoczyńska, Anna $u National Reference Centre for Bacterial Meningitis, National Medicines Institute, 00-725 Warsaw, Poland
- 700 1_
- $a Suga, Shigeru $u Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Tsu, Mie 514-0125, Japan
- 700 1_
- $a van der Linden, Mark $u National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany
- 700 1_
- $a Verani, Jennifer R $u National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA $u Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), Division of Global Health Protection (DGHP), Nairobi, Kenya
- 700 1_
- $a von Gottberg, Anne $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 2192 Johannesburg, South Africa $u School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg 2000, South Africa
- 700 1_
- $a Winje, Brita A $u Department of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway
- 700 1_
- $a Yildirim, Inci $u Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT 06504, USA
- 700 1_
- $a Zerouali, Khalid $u Bacteriology-Virology and Hospital Hygiene Laboratory, Ibn Rochd University Hospital Centre, Casablanca 20250, Morocco $u Department of Microbiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca 20000, Morocco
- 700 1_
- $a Hayford, Kyla $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a The Pserenade Team,
- 773 0_
- $w MED00198767 $t Microorganisms $x 2076-2607 $g Roč. 9, č. 4 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33801760 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104128 $b ABA008
- 999 __
- $a ind $b bmc $g 1676533 $s 1138524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 4 $e 20210327 $i 2076-2607 $m Microorganisms $n Microorganisms $x MED00198767
- GRA __
- $a 001 $p World Health Organization $2 International
- GRA __
- $a INV-010429 / OPP1189065 $p Bill and Melinda Gates Foundation
- LZP __
- $a Pubmed-20210726
